TY - JOUR
T1 - Comparison of web-based information about cell-free DNA prenatal screening
T2 - implications for differences of sex development care
AU - Kim, Soojin
AU - Finney, Esther L.
AU - Naha, Ushasi
AU - Rosoklija, Ilina
AU - Honegger, Kyle S.
AU - Goetsch Weisman, Allison
AU - Holl, Jane Louise
AU - Finlayson, Courtney
AU - Chen, Diane
AU - Johnson, Emilie Katherine
N1 - Publisher Copyright:
Copyright © 2023 Kim, Finney, Naha, Rosoklija, Honegger, Goetsch Weisman, Holl, Finlayson, Chen and Johnson.
PY - 2023
Y1 - 2023
N2 - Objective: Cell-free DNA (cfDNA) prenatal screening is a commercially available noninvasive test that detects fetal genetic material in maternal blood. While expectant parents often use it for “gender” determination, there is little information about unintended consequences of testing, such as revelation of a difference of sex development (DSD). The study aimed to characterize currently available website information about cfDNA and compare the cfDNA-related content. Methods: A systematic search for websites with information about cfDNA was conducted using search terms generated by a natural language processing analysis of the results of an Amazon Mechanical Turk (MTurk) survey of 1,000 parents and then performing a “Google” search, using the terms. Commercial cfDNA testing companies (CC) websites were also identified by consulting a genetic counselor (AGW). Data were collected on about each website’s characteristics and information about cfDNA. Information about cfDNA was compared between websites. Data were analyzed using descriptive statistics, Fisher’s exact test or Kruskal-Wallis test were applied, as appropriate. Results: Sixty websites were identified. After eliminating duplicates, 11 commercial company (CC) websites were identified. Nineteen other websites were reviewed of which six overlapped with five CC websites. Most of the websites had non-professional authors (73.7%), such as laypersons and CC representatives. CC websites were significantly more likely than search term-identified websites to state that cfDNA can screen for trisomy 21 (p=0.002), trisomy 18 (p<0.0001), trisomy 13 (p<0.001), sex chromosome aneuploidies (p<0.001), and microdeletions (p=0.002). Conclusions: This study shows that most website currently available information for expectant parents about cfDNA prenatal screening is produced by non-professional organizations. There are significant differences between the information provided by CC and Google search websites, specifically about the number of conditions screened for by cfDNA. Improving availability and quality of information about cfDNA could improve counseling future expectant parents. Inclusion of information about the potential for detection of a DSD is needed.
AB - Objective: Cell-free DNA (cfDNA) prenatal screening is a commercially available noninvasive test that detects fetal genetic material in maternal blood. While expectant parents often use it for “gender” determination, there is little information about unintended consequences of testing, such as revelation of a difference of sex development (DSD). The study aimed to characterize currently available website information about cfDNA and compare the cfDNA-related content. Methods: A systematic search for websites with information about cfDNA was conducted using search terms generated by a natural language processing analysis of the results of an Amazon Mechanical Turk (MTurk) survey of 1,000 parents and then performing a “Google” search, using the terms. Commercial cfDNA testing companies (CC) websites were also identified by consulting a genetic counselor (AGW). Data were collected on about each website’s characteristics and information about cfDNA. Information about cfDNA was compared between websites. Data were analyzed using descriptive statistics, Fisher’s exact test or Kruskal-Wallis test were applied, as appropriate. Results: Sixty websites were identified. After eliminating duplicates, 11 commercial company (CC) websites were identified. Nineteen other websites were reviewed of which six overlapped with five CC websites. Most of the websites had non-professional authors (73.7%), such as laypersons and CC representatives. CC websites were significantly more likely than search term-identified websites to state that cfDNA can screen for trisomy 21 (p=0.002), trisomy 18 (p<0.0001), trisomy 13 (p<0.001), sex chromosome aneuploidies (p<0.001), and microdeletions (p=0.002). Conclusions: This study shows that most website currently available information for expectant parents about cfDNA prenatal screening is produced by non-professional organizations. There are significant differences between the information provided by CC and Google search websites, specifically about the number of conditions screened for by cfDNA. Improving availability and quality of information about cfDNA could improve counseling future expectant parents. Inclusion of information about the potential for detection of a DSD is needed.
KW - cell-free DNA (cfDNA)
KW - counseling
KW - disorder of sex development
KW - fetal sex determination
KW - noninvasive prenatal test (NIPT)
KW - patient education
KW - sex chromosome aneuploidies
KW - web-based information
UR - http://www.scopus.com/inward/record.url?scp=85183415520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85183415520&partnerID=8YFLogxK
U2 - 10.3389/fruro.2023.1144618
DO - 10.3389/fruro.2023.1144618
M3 - Article
AN - SCOPUS:85183415520
SN - 2673-9828
VL - 3
JO - Frontiers in Urology
JF - Frontiers in Urology
M1 - 1144618
ER -